Lysergic acid diethylamide is under clinical development by MindBio Therapeutics and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lysergic acid diethylamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lysergic acid diethylamide overview
Lysergic acid diethylamide is under development for the treatment of anxiety disorders, major depressive disorder, and unspecified cancer. The therapeutic candidate acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A).
MindBio Therapeutics overview
MindBio Therapeutics is a Pharmaceuticals and Healthcare company that offers drug development services. The company is Headquartered in Melbourne, Victoria, Australia.
For a complete picture of Lysergic acid diethylamide’s drug-specific PTSR and LoA scores, buy the report here.